Abstract Functional genetic polymorphisms involved in folate and methionine metabolism play an important role in both DNA synthesis and methylation, and affect the risk of various malignancies including lymphoproliferative disorders such as systemic non-Hodgkin's lymphoma. In a retrospective analysis of 185 immunocompetent patients with primary central nervous system lymphoma (PCNSL) and 212 population controls we therefore investigated eight genetic polymorphisms affecting methionine metabolism for potential association with the development of PCNSL. We observed underrepresentation of the G-allele of the methyltetrahydrofolate homocysteine S-methyltransferase (MTR) c.2756A [ G (D919G) missense polymorphism among PCNSL patients (P = 0.045; odds ratio (OR) = 0.65; 0.43-0.99). Furthermore, for the methylenetetrahydrofolate reductase (MTHFR) c.1298A [ C (E429A) polymorphism the mutated C-allele was found more frequently among PCNSL patients than among population controls (P = 0.026; OR = 1.57; 1.05-2.34). There were no associations of the other polymorphisms investigated (MTHFR c.677C [ T, transcobalamin 2 (Tc2) c.776C [ G, cystathionin betasynthase (CBS) c.844_855ins68, reduced folate carrier-1 (RFC-1) c.80G [ A, thymidylate synthase (TYMS) 28-bp repeat, and dihydrofolate reductase (DHFR) c.594 ? 59del19 bp) and the presence of PCNSL. This analysis is the largest to date to evaluate associations between genetic variants of folate and methionine metabolism and PCNSL. Our results suggest the hypothesis that folate and methionine metabolism is relevant to susceptibility to PCNSL.
Introduction
Primary central nervous system lymphoma (PCNSL) is an aggressive subtype of non-Hodgkin's lymphoma (NHL) arising within the central nervous system (CNS). The vast majority are diffuse large B-cell lymphomas (DLBCL) derived from germinal center B cells [1] , and pathogenic factors are largely unclear, so far. In a recent retrospective analysis no association between PCNSL and human leukocyte antigens (HLA) was found [2] . PCNSL characteristically reveals genetic instability with chromosomal imbalances [3] . Thus, metabolic factors and conditions contributing to the maintenance of DNA integrity may affect the development and growth of PCNSL cells via altered DNA synthesis and methylation of oncogenes and tumor suppressor genes. Aberrant folate and methionine metabolism could interfere with both processes. Genetic variants that functionally affect enzymes, transporter proteins, or receptor proteins involved in folate and methionine metabolism are associated with different types of extracranial human cancer, for example systemic NHL, acute leukemia, and colorectal cancer [4] [5] [6] [7] [8] .
In immunocompetent patients, an association of PCNSL with the methyltetrahydrofolate homocysteine S-methyltransferase (MTR) c.2756A [ G variant has been reported [9] , and this polymorphism has also been reported to alter susceptibility to other intracranial tumors including glioblastoma and anaplastic meningioma [10, 11] .
In this explorative study our objective was to analyze the frequency of eight functional genetic variants of folate and methionine metabolism in a group of 185 patients with PCNSL compared with 212 healthy controls, making this study the largest to date to evaluate this association.
Materials and methods

Study population
We investigated 185 consecutive immunocompetent PCNSL patients of Caucasian origin recruited for the German multicenter phase IV trial (G-PCNSL-SG-1) between 08/2000 and 12/2004 (43.8% female; median age at diagnosis 60.4 years, range 18-81 years). The objective of the G-PCNSL-SG-1 study is to analyze the value of whole-brain radiotherapy after six courses of high-dose methotrexate (MTX) in newly diagnosed PCNSL. Inclusion criteria for the G-PCNSL-SG-1 study were newly diagnosed and histologically or cytologically (in the cerebrospinal fluid) confirmed PCNSL in an immunocompetent patient and adequate renal and bone marrow function. Exclusion criteria were systemic manifestation of NHL, additional malignancies, and immunodeficiency or concomitant immunosuppressive therapy. Two-hundred and twelve apparently healthy Caucasian Bonn-area residents (45.8% female; median age 63.0 years, range 39-85 years) without a history of cancer, recruited as control population for an ongoing study on atherosclerosis, served as controls [12, 13] . The same cohort had already been used as control group for a small case-control study analyzing folatemetabolizing pathway polymorphisms in patients with PCNSL [9] . Characteristics of the study population have been summarized in Table 1 .
The study was approved by the respective local ethics committees, and all participants gave written informed consent.
DNA extraction and genotyping
Blood samples were collected prospectively upon enrollment in the G-PCNSL-SG-1 trial before treatment was started. Genomic DNA was extracted from mononuclear cells by use of the QIAamp Ò DNA Blood Mini Kit (Qiagen, Hilden, Germany). Genotyping of eight polymorphisms (methylenetetrahydrofolate reductase (MTHFR) c.677C DNA by applying polymerase chain reaction (PCR) and subsequent restriction enzyme digestion or by allele-specific PCR followed by agarose gel electrophoresis [14] [15] [16] [17] [18] [19] [20] .
Statistical analysis
The distribution of age and gender in the patient and the control groups was compared by applying a t-test for two independent samples and Pearson's v 2 test, respectively. For the tested genotypes the Hardy-Weinberg equation was calculated for all PCNSL patients and controls together with a v 2 goodness-of-fit test (df = 2). The two-sided Pearson's v
2 test was used to analyze the distribution of the respective genotypes in the patient and control groups for statistical significance. Threshold was defined by alpha \0.05. Because of the low frequencies of the MTR c.2756GG and the MTHFR c.1298CC homozygous variants, we also evaluated the presence of at least one mutant allele (AG/GG or AC/CC) versus homozygosity for the wildtype allele (AA) in the patient and the control sample (Pearson's v 2 test; df = 1). All analyses were purely explorative, so that correction for multiple testing was not regarded as necessary, and all findings require reevaluation in future studies.
Odds ratios (OR) with 95% confidence intervals (CI) were calculated for the combined MTR c.2756AG/GG and MTHFR c.1298AC/CC genotypes.
Furthermore, multinominal regression analysis with alpha = 0.05 was used to test the independent association of the respective polymorphisms with PCNSL and to exclude confounding effects of age, gender, or multiple testing.
All statistical calculations were performed by use of the software Statistical Package for the Social Sciences (SPSS) version 16.0 (SPSS, Chicago, IL, USA).
Results
There were no significant differences concerning age and gender between the patient and control groups. Genotype distributions in all PCNSL patients and controls are shown in Table 2 . The distribution of allelotypes of the polymorphisms did not significantly deviate from the HardyWeinberg equilibrium (data not shown). Allelic frequencies of the MTHFR c.677C
TYMS 28-bp repeat, and the DHFR c.594 ? 59del19 bp polymorphism in the control group are similar to those found in another independent healthy German population [21] and those reported for other Caucasian populations [15, 16, 22] .
The MTR c.2756A [ G polymorphism (G-allele) was less frequent in PCNSL patients than in controls (patients AA/AG/GG: 71.3/24.9/3.8 and controls AA/AG/GG: 61.8/ 34.0/4.2; v 2 = 4.17 (Pearson), P = 0.125 for trend, df = 2). In Pearson's v 2 test of the pooled genotypes MTR c.2756AA versus AG/GG without correction for multiple testing, the MTR c.2756G allele was significantly underrepresented in the patient sample; at least one mutant allele (the MTR c.2756AG and GG genotypes) was detected in 28.7% of PCNSL patients compared with 38.2% of controls (v 2 = 4.04, P = 0.045, df = 1; Table 3 ). Overall, multinominal logistic regression analysis with simultaneous analysis of all eight polymorphisms together with age and gender as co-variables reproduced the above findings (v 2 = 4.449, P = 0.035 for pooled genotypes, df = 1).
Furthermore, for the MTHFR c.1298A [ C polymorphism, the mutated C-allele was observed more frequently among PCNSL patients than in controls (patients AA/AC/ CC: 38.8/52.1/9.1 and controls AA/AC/CC: 50.5/42.0/7.5; v 2 = 5.38 (Pearson), P = 0.068 for trend, df = 2). This trend was significant in the uncorrected explorative analysis (MTHFR c.1298AA versus AC and CC genotypes: v 2 = 5.00, P = 0.026, df = 1; Table 3 ) and in multinomial logistic regression analysis of the pooled genotypes (v 2 = 5.179, P = 0.023). A reduced risk estimate was found for the MTR c.2756AG/GG genotype when MTR c.2756AA was the referent group (OR = 0.65; 0.43-0.99; Table 3 ), whereas a small increased risk estimate for PCNSL was associated with the MTHFR c.1298AC/CC genotype versus homozygosity for the wildtype allele AA (OR = 1.57; 1.05-2.34; Table 3 ).
There were no significant associations of the other polymorphisms investigated (MTHFR c.677C
TYMS 28-bp repeat, and DHFR c.594 ? 59del19 bp; Table 2 ) with the development of PCNSL.
Discussion
The findings presented here suggest an association between the MTR c.2756A [ G (D919G) and MTHFR c.1298A [ C (E429A) polymorphisms and the presence of PCNSL, with the MTR c.2756G allele being less frequent and the mutated MTHFR c.1298C allele more common in patients than in population controls.
As for the MTR c.2756A [ G polymorphism, these data confirm the results of a previous case-control study on 31 German PCNSL patients which found significantly fewer carriers of the MTR c.2756A [ G missense polymorphism among patients [9] . Of note, control samples of both studies overlap, so the observed effect could have been because of coincidental overrepresentation of the G-allele in the control group. However, this seems unlikely, because allelic frequencies of the MTR c.2756A [ G polymorphism in this control group are similar to those of another independent healthy German population [21] . Interestingly, in this population sample the presence of the MTR c.2756G allele has been correlated with disease-free longevity. MTR catalyzes the remethylation of homocysteine to methionine. The G-allele of MTR c.2756A [ G has been suggested to lead to higher MTR activity, supposedly changing the kinetics of nucleic acid and S-adenosylmethionine (SAM) synthesis. SAM is necessary for DNA methylation. Thus, the MTR variant may affect both DNA synthesis and methylation, whereas any concrete effect of the variant on tumorigenesis remains speculative. Our results showing a reduced frequency of the MTR c.2756G allele in patients with PCNSL are in agreement with results from previous studies on the MTR missense dimorphism c.2756A [ G which was found at lower frequency in patients with colorectal cancer [7] , cervical intraepithelial neoplasia [23] , and follicular NHL [8] , and (among primary brain tumors) with GBM and anaplastic meningioma [10, 11] .
The second genetic variant in this study, MTHFR c.1298A [ C, with a significant positive association with PCNSL in explorative data analysis has previously been reported to be associated with some types of human cancer [4] [5] [6] 24] . MTHFR catalyzes the conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, which acts as a methyl donor for the transformation of homocysteine to methionine. In the MTHFR gene the polymorphisms c.677C [ T and c.1298A [ C both lead to reduced enzyme activity. While these variants were both observed more frequently in our patient group, this effect did not reach statistical significance for the MTHFR c.677C [ T polymorphism. This could be because the sample size was too small and should be reevaluated in further patient groups, The distribution of the different genotypes among PCNSL patients and controls is given as relative amount although PCNSL is a rare disease and large patient cohorts are difficult to obtain. Possible mechanisms underlying an association of the MTHFR variants include effects on folate derivatization, on homocysteine remethylation to methionine, and on SAM availability for DNA synthesis. More basic research is necessary to elucidate such putative interactions. However, as already pointed out, the reported variants do not exclusively affect pathways in PCNSL development but are apparently relevant for tumorigenesis in general. Moreover, because of the case-control design of our study, and because of the ''matching procedure'' we employed (which was not done between individual cases and controls, but between the entire group of cases and the entire group of controls) certain caveats are necessary, including the possibility of unrecognized selection bias and unknown confounders which cannot be fully controlled for. As a result, a definitive relationship between ''exposure'' (i.e., MTR and MTHFR polymorphisms) and PCNSL has not been established. This study is an explorative, hypothesisgenerating investigation. Our results require replication in additional large trials and in pooled analyses.
In summary, this analysis is the largest to date to evaluate associations between polymorphisms in folatemetabolizing genes and PCNSL, and suggests that some functional genetic variants of folate and methionine metabolism alter susceptibility to PCNSL. Specifically, the MTR c.2756G allele may reduce susceptibility (a protective effect) whereas the MTHFR c.1298C allele may increase susceptibility. Because folate and methionine metabolism is closely associated with the availability of methionine, folate, and vitamin B12, it might even be possible that nutritional factors modify the effect of PCNSL, as has been described for other tumors.
Folate and methionine metabolism also seems to affect anticancer therapy with MTX which is still the most efficient drug in the chemotherapeutic treatment of PCNSL and directly interferes with methionine metabolism. Therefore, further studies on the effect of folate and methionine metabolism on the incidence and treatment outcome of PCNSL are warranted.
